Malaria Drug Accelerator (MalDA)

The Malaria Drug Accelerator (MalDA) is a collaboration of 13 scientific laboratories funded by the Bill and Melinda Gates foundation to advance the development of new antimalarial drugs.

MalDA Members

Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation

Gang Liu, Ph.D.
Program Officer

Prof. David Fidock Lab at Columbia University
Prof. David Fidock Lab at Columbia University

Manu Vanaerschot, Ph.D.

Pennsylvania State University
Pennsylvania State University

Prof. Manuel Llinás

Prof. Dyann Wirth Lab at Harvard University
Prof. Dyann Wirth Lab at Harvard University

Amanda Lukens, Ph.D.

Prof. Daniel Goldberg Lab at Washington University in St. Lous
Prof. Daniel Goldberg Lab at Washington University in St. Lous

Eva Istvan, Ph.D.

Prof. Elizabeth Winzeler Lab at UC San Diego
Prof. Elizabeth Winzeler Lab at UC San Diego

Sabine Ottilie, Ph.D.
Program Manager

GlaxoSmithKline
GlaxoSmithKline

Francisco Javier Gamo-Benito, Ph.D.

Wellcome Trust Sanger Institute
Wellcome Trust Sanger Institute

Marcus Lee, Ph.D.

The Medicines For Malaria Venture
The Medicines For Malaria Venture

Jeremy Burrows, Ph.D.

Global Health Drug Discovery Institute
Global Health Drug Discovery Institute

Xin-Jie Chu, Ph.D.

Structure-Based Drug Discovery Consortium
Structure-Based Drug Discovery Consortium

Chris Walpole, Ph.D.

MIT
MIT

Prof. Jacquin Niles, Ph.D.

Drug Discovery Unit, University of Dundee
Drug Discovery Unit, University of Dundee

Ian Gilbert, Ph.D.

Message us for inquiries regarding the MalDA project: saottilie@ucsd.edu

Contact Us

Start typing and press Enter to search